Evidence map›Paper›PMID 32831852›Full record

ArticleStem cells international2020

The Efficacy of Mesenchymal Stem Cells in Therapy of Acute Kidney Injury Induced by Ischemia-Reperfusion in Animal Models.

Tianbiao Zhou, Chunling Liao, Shujun Lin, Wenshan Lin, Hongzhen Zhong, Shuangyi Huang

Abstract read
In one paragraph

Article in Stem cells international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tianbiao ZhouDepartment of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China.ORCID https://orcid.org/0000-0001-8065-1644
Chunling LiaoDepartment of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China.
Shujun LinDepartment of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China.
Wenshan LinDepartment of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China.
Hongzhen ZhongDepartment of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China.
Shuangyi HuangDepartment of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs), discovered and isolated from the bone marrow in the 1960s and with self-renewal capacity and multilineage differentiation potential, have valuable immunomodulatory abilities. Acute kidney injury (AKI) refers to rapid renal failure, which exhibits as quickly progressive decreasing excretion in few hours or days. This study was performed to assess the efficacy of MSCs in the treatment of AKI induced by ischemia-reperfusion using a meta-analysis method. A literature search using corresponding terms was performed in the following databases: Embase, Cochrane Library, PubMed, and ISI Web of Science databases up to Dec 31, 2019. Data for outcomes were identified, and the efficacy of MSCs for AKI was assessed using Cochrane Review Manager Version 5.3. Nineteen studies were eligible and recruited for this meta-analysis. MSC treatment can reduce the Scr levels at 1 day, 2 days, 3 days, 5 days, and >7 days (1 day: WMD = -0.56, 95% CI: -0.78, -0.34,

Identifiers

PMID32831852
PMCPMC7422493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.